Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

About this update from Arrowhead Pharmaceuticals, Inc.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1609,"height":335,"url":"https://media.zenfs.com/en/business-wire.com/77a0ca5b804b125e9c1b3bfff76f2460"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dBp3.bivwDMSNrK1zwa9Iw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIwMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/77a0ca5b804b125e9c1b3bfff76f2460","width":960,"height":200},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/6krfcOE.e6fFDepZUD9mnw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/77a0ca5b804b125e9c1b3bfff76f2460","width":1200,"height":250}},"lazy":false},{"type":"text","content":"- ARO-DIMER-PA is the first clinical candidate designed to silence the expression of two genes with a single RNAi molecule","length":122,"tagName":"p","attribs":{}},{"type":"text","content":"- In preclinical studies, ARO-DIMER-PA potently lowered serum PCSK9 and APOC3, and ameliorated high levels of non-HDL-cholesterol, LDL-cholesterol, and triglycerides in hyperlipidemic nonhuman primates","length":201,"tagName":"p","attribs":{}},{"type":"text","content":"- Study initiation further highlights Arrowhead’s innovation and leadership in the delivery of siRNA and the versatility of Arrowhead’s proprietary TRiM™ technology","length":164,"tagName":"p","attribs":{}},{"type":"text","content":"PASADENA, Calif., January 27, 2026--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-DIMER-PA, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia. ARO-DIMER-PA is designed to silence expression of both proprotein convertase subtilisin kexin 9 (PCSK9) and apolipoprotein C3 (APOC3) genes. This represents an important step forward for the field of RNAi therapeutics, as it is the first clinical candidate to target two genes simultaneously in one molecule, enabled by Arrowhead’s innovative and proprietary Targeted RNAi Molecule (TRiM™) platform.","length":787,"tagName":"p"},{"type":"text","content":"Mixed hyperlipidemia is a highly prevalent disorder characterized by elevated levels of b...

More updates from Arrowhead Pharmaceuticals, Inc.